All authorized agents for medicine are hereby informed that No new registrations for following products/combination products will be accepted by NMRA,

1. Moxifloxacine + Dexamethasone

2. Doxylamine Succinate + Pyridoxime Hydrochloride

3. Mefenamic acid tablets 250 mg

4. Warfarin Sodium Tablets 10 mg

CEO

NMRA

(Date: 15 March 2021)